“I’m tired of taking pills every day”: participants’ choices and experiences of the Cabotegravir plus Rilpivirine Long-Acting (CAB + RPV LA) efficacy and safety trial in sub-Saharan Africa (CARES)

AUTHORS

E.-L. Durden¹, D. Kaawa-Mafigiri², A. Mulwo³, N. Gumede¹, I.K. Mambule^4,5, K. Opiyo⁴, C. Kityo⁴, N.I. Patton⁶, K. Mulungu⁴, L. Klasko-Foster⁷, S. Asasira⁸, A. Alinaitwe⁹, M. Okwero¹⁰, P. Onyango¹¹, V. Kirui¹², M. Omol¹³, N. Tom¹⁴, N. Jeenarain¹⁵, A. Idahosa¹⁶, I. Eshun-Wilsonova¹⁷, F. Addo Boateng^18,19


INSTITUTIONS

¹University of KwaZulu-Natal, Centre for Communication and Media in Society, Durban, South Africa, ²Makerere University, School of Social Sciences, Kampala, Uganda, ³Moi University, School of Information Sciences, Eldoret, Kenya, ⁴Joint Clinical Research Centre, Kampala, Uganda, ⁵Liverpool School of Tropical Medicine, Clinical Sciences department, Liverpool, United Kingdom, ⁶National University of Singapore, Infectious Diseases Translational Research Programme and Department of Medicine,, Singapore, Singapore, ⁷Johnson&Johnson Global Health Equity, New Brunswick, United States, ⁸Joint Clinical Research Centre, Lubowa, Kampala, Uganda, ⁹Joint Clinical Research Centre, Fort Portal, Kampala, Uganda, ¹⁰Infectious Diseases Institute, Kampala, Uganda, ¹¹Aga Khan University Hospital, Nairobi, Kenya, ¹²Moi University School of Medicine, Eldoret, Kenya, ¹³Kenya Medical Research Institute/US Army Medical Research Directorate, Kericho, Kenya, ¹⁴University of the Witwatersrand, Ezintsha, Faculty of Health Sciences, Johannesburg, South Africa, ¹⁵Chatsworth Clinical Research Site, South African Medical Research Council (SAMRC), Durban, South Africa, ¹⁶Johnson & Johnson Company West Africa Ltd, Accra, Ghana, ¹⁷Johnson & Johnson, Cape Town, South Africa, ¹⁸Johnson & Johnson Middle East FZ LLC, Accra, Ghana, ¹⁹Novartis Ghana Limited, Accra, Ghana